Editorial: The best-laid plans . . . Often go Awry . . .

Journal of Thoracic Oncology

Volumn 4, Issue 7, 2009, Pages 783-784

  Urbanic, James J ^a   Lally, Brian ^b   Blackstock, A William ^a  

^a WAKE FOREST BAPTIST HEALTH   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GEMCITABINE; RADIOSENSITIZING AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE;

CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG RESPONSE; EDITORIAL; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MULTIMODALITY CANCER THERAPY; PNEUMONIA; PRIORITY JOURNAL; RADIATION DOSE; RADIATION INJURY; SURVIVAL TIME; TREATMENT RESPONSE; CANCER STAGING; LUNG TUMOR; NOTE; PATHOLOGY; RADIATION PNEUMONIA; SURVIVAL RATE;

CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; RADIATION PNEUMONITIS; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY DOSAGE; SURVIVAL RATE;

EID: 68549125426     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181a99bf0     Document Type: Editorial

References (12)

1. Arrieta O, Gallardo-Rincón D, Villarreal-Garza C, et al. High frequency of radiation pneumonitis in patients with locally advanced non-smallcell lung cancer treated with concurrent radiotherapy and gemcitabine after induction with gemcitabine and carboplatin. J Thorac Oncol 2009;4:845-852.
2. Scalliet P, Goor C, Galdermans D, et al. Gemzar (Gemcitabine) with thoracic radiotherapy-A phase II pilot study in chemonaive patients with advanced non small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1998;17:(Abstract 1923).
3. Blackstock AW, Ho C, Butler J, et al. Phase Ia/Ib chemo-radiation trial of gemcitabine and dose-escalated thoracic radiation in patients with stage III A/B non-small cell lung cancer. J Thorac Oncol 2006;1:434-440. (Pubitemid 47181420)
4. Vokes EE, Herndon JE II, Crawford J, et al. Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431. J Clin Oncol 2002;20:4191-4198. (Pubitemid 35191021)
5. Socinski MA, Blackstock AW, Bogart JA, et al. Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105. J Clin Oncol 2008;26: 2457-2463.
6. Zinner RG, Komaki R, Cox JD, et al. Dose escalation of gemcitabine is possible with concurrent chest three-dimensional rather than two-dimensional radiotherapy: a phase I trial in patients with stage III non-smallcell lung cancer. Int J Radiat Oncol Biol Phys 2009;73:119-127.
7. Choy H, Jain AK, Moughan J, et al. RTOG 0017: a phase I trial of concurrent gemcitabine/carboplatin or gemcitabine/paclitaxel and radiation therapy ("ping-pong trial") followed by adjuvant chemotherapy for patients with favorable prognosis inoperable stage IIIA/B non-small cell lung cancer. J Thorac Oncol 2009;4:80-86.
8. Zwitter M, Kovac V, Smrdel U, Strojan P. Gemcitabine, cisplatin, and hyperfractionated accelerated radiotherapy for locally advanced nonsmall cell lung cancer. J Thorac Oncol 2006;1:662-666. (Pubitemid 47163953)
9. Lawrence TS, Chang EY, Hahn TM, Hertel LW, Shewach DS. Radiosensitization of pancreatic cancer cells by 2', 2'-difluoro-2'-deoxycytidine. Int J Radiat Oncol Biol Phys 1996;34:867-872. (Pubitemid 26089225)
10. Blackstock AW, Lightfoot H, Case LD, et al. Tumor uptake and elimination of 2', 2'-difluoro-2'-deoxycytidine (gemcitabine) after deoxycytidine kinase gene transfer: correlation with in vivo tumor response. Clin Cancer Res 2001;7:3263-3268. (Pubitemid 32963852)
11. Fields MT, Eisbruch A, Normolle D, et al. Radiosensitization produced in vivo by once- vs. twice-weekly 2'2'-difluoro-2'-deoxycytidine (gemcitabine). Int J Radiat Oncol Biol Phys 2000;47:785-791. (Pubitemid 30317500)
12. Mason KA, Milas L, Hunter NR, et al. Maximizing therapeutic gain with gemcitabine and fractionated radiation. Int J Radiat Oncol Biol Phys 1999;44:1125-1135. (Pubitemid 29342915)